WMWenjing Mao

Wenjing Mao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenjing Mao has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Airong Qian

    Lab for Bone Metabolism, Xi’an Key Laboratory of Special Medicine and Health Engineering, Key Lab for Space Biosciences and Biotechnology, Research Center for Special Medicine and Health Systems Engineering, NPU-UAB Joint Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University, Xi’an 710072, Shaanxi, China

    1 shared publication
  • Chunsheng Wei

    ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Fanlei Ran

    Key Laboratory of RNA Biology and Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100000, China

    1 shared publication
  • Jiajia Wang

    ENT institute and Department of Otorhinolaryngology Eye & ENT Hospital, Fudan University

    1 shared publication
  • Jingru Ma

    Department of Otolaryngology-Head and Neck Surgery, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, People’s Republic of China

    1 shared publication
  • Kang Ru

    Lab for Bone Metabolism, Xi’an Key Laboratory of Special Medicine and Health Engineering, Key Lab for Space Biosciences and Biotechnology, Research Center for Special Medicine and Health Systems Engineering, NPU-UAB Joint Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University, Xi’an 710072, Shaanxi, China

    1 shared publication

Latest Publications

  • Systemic bevacizumab for treatment of recurrent respiratory papillomatosis

    by Xiaoyun Zhao, Jiajia Wang, Qi Chen, Xiufa Wu, Wenjing Mao, Jingru Ma, Rui Fang, Peijie He, Chunsheng Wei

    Objectives To characterize treatment response of recurrent respiratory papillomatosis (RRP) including adult-onset RRP (AORRP) and juvenile-onset RRP (JORRP) to systemic bevacizumab (bev), and share our treatment regimen experience. Methods Patients were enrolled in bev treatment based on a pathologically confirmed diagnosis of squamous papilloma. According to lesion characteristics and medical history, systemic bev was used as preoperative adjuvant therapy, postoperative adjuvant therapy, or primary therapy. The assessment of treatment response relied on the morphological changes of lesions. Vocalization and voice-related quality of life were evaluated using the voice handicap index-30 (VHI-30) for adults and the pediatric VHI (pVHI) for children. Adverse effect was monitored through patient self-reported symptoms and regular follow-ups. Results This study included 24 patients, comprising nine AORRP and 15 JORRP cases. In AORRP, all patients (100%) exhibited various degrees of response to systemic bev, with 5 (55.56%) achieving complete response (CR). Among JORRP patients, 14 (93.33%) showed a response to systemic bev, with 8 (53.33%) achieving CR and currently being followed up. No instances of aggravation were observed during systemic bev treatment. A total of 21 patients (21/24, 87.50%) reported voice improvement, accompanied by reduced VHI-30 or pVHI scores across all aspects, including total, functional, physical, and emotional dimensions. No grade 3 or higher adverse events occurred. The most common adverse events were grade 1 gum bleeding (n = 4, 16.67%) and grade 1 proteinuria (n = 4, 16.67%). Conclusions Systemic bev can be used as a powerful therapy for both AORRP and JORRP. The findings provide a reference to the systemic bev treatment for RRP.


  • Microgravity Inhibits Cell Proliferation and Promotes Senescence and Apoptosis in Embryonic Stem Cells

    by Wenjing Mao, Ying Huai, Lili An, Xuehao Wang, Kang Ru, Suryaji Patil, Wenjuan Zhang, Fanlei Ran, Zhihao Chen, Airong Qian

    With advancements in deep space exploration missions, long-term spaceflights pose potential hazards to the reproductive and developmental functions of astronauts. Embryonic stem cells (ESCs), which are crucial to the development and growth of individual organisms, are observably altered by a microgravity environment. However, the role and mechanisms of microgravity in other activities of ESCs are still unclear. Here, mouse embryonic stem cells (mESCs) were used to investigate and understand the effect of microgravity on their activities. Combined with the SJ-10 satellite and random position machine, which were utilized for spaceflight and microgravity simulation, respectively, the bioinformatic tools were also used to assess the effect that microgravity might have on mESC activities. Based on differentially expressed genes (DEGs) analysis, 114 DEGs were significantly up-regulated and 859 DEGs were significantly down-regulated in mESCs after being subjected to spaceflight. The activities, such as cell proliferation, senescence, and apoptosis, were selected and confirmed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. It demonstrated a reduced proliferation capability of mESCs but increased the number of senescent and apoptotic cells after being subjected to simulated microgravity. Real-time polymerase chain reaction analysis of the screened activity-related DEGs demonstrated approximately consistent trends of these gene expressions in both spaceflight and simulated microgravity, as was predicted by bioinformatics analysis. Overall, these findings suggest that microgravity inhibits the proliferation of mESCs and induces senescence and apoptosis, shedding light on the impact of microgravity on the fundamental functions of mESCs in reproductive and embryonic development.